Primary diffuse large b-cell lymphoma of the lip: a case report and literature review - Report - MDSpire

Primary diffuse large b-cell lymphoma of the lip: a case report and literature review

  • By

  • Pingping Liu

  • Changjiang Xu

  • Liming Yu

  • Xiuying Wang

  • Yan Wang

  • Xiaofei Yan

  • June 8, 2026

  • 0 min

Share

Clinical Report: Primary Diffuse Large B-Cell Lymphoma Affecting the Lip

Overview

This report details a rare case of primary diffuse large B-cell lymphoma (DLBCL) affecting the lip in a 65-year-old male, initially misdiagnosed as a maxillary space infection. The patient was successfully treated with R-CHOP chemotherapy, achieving complete remission.

Background

Primary DLBCL of the lip is an exceptionally rare condition, comprising less than 1% of extranodal DLBCL cases. Its atypical presentation often leads to misdiagnosis, delaying appropriate treatment. Understanding this condition is crucial for timely diagnosis and management, particularly in patients presenting with persistent lip lesions.

Data Highlights

No numerical data or trial data was presented in the article.

Key Findings

  • Primary DLBCL of the lip is a rare subtype of extranodal non-Hodgkin lymphoma.
  • Initial misdiagnosis can occur due to overlapping symptoms with benign conditions.
  • Imaging studies such as ultrasound and MRI are essential for diagnosis.
  • Histopathological examination confirmed the diagnosis of the germinal center B-cell subtype of DLBCL.
  • The patient achieved complete remission following R-CHOP chemotherapy.

Clinical Implications

Healthcare professionals should maintain a high index of suspicion for malignancy in persistent lip lesions. Early biopsy and multidisciplinary evaluation are critical for accurate diagnosis and timely treatment of rare conditions like primary DLBCL of the lip.

Conclusion

This case underscores the importance of considering lymphoma in differential diagnoses for lip lesions and highlights the successful management of a rare malignancy through a multidisciplinary approach.

Related Resources & Content

  1. Blood Cancer Journal, 2020 -- Determinants of Diffuse Large B-Cell Lymphoma: Genetic and Epigenetic Factors
  2. Temple Health -- Case Study: ICU-Based Chemotherapy for High-Risk Cardiac DLBCL Patient
  3. The ASCO Post, 2015 -- Answers: Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
  4. Frontiers in Immunology -- Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report
  5. SEOM–GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025) - PMC
  6. Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus R-CHOP on outcomes
  7. Management of relapsed or refractory large B‐cell lymphoma: A British Society for Haematology Guideline | CoLab
  8. SEOM–GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025) - PMC
  9. Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin▼ plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes
  10. Management of relapsed or refractory large B‐cell lymphoma: A British Society for Haematology Guideline | CoLab

Original Source(s)

Related Content